Profile Image

Dr Jennette Sakoff

Conjoint Lecturer

School of Environmental and Life Sciences (Chemistry)

Career Summary

Biography

Research Expertise
Dr Sakoff is an experienced cell biologist and Chief Hospital Scientist in the Department of Medical Oncology at the Calvary Mater Newcastle Hospital. Dr Sakoff is the leader of the Experimental Therapeutics Group. She has made significant contributions to cancer research particularly in the development of small molecules for the treatment of cancer. Areas of expertise includes cell culture, drug screening, cell biology, proteomics, cell cycle analysis, drug combination studies, clinical toxicity.

Teaching Expertise
Selected lectures in drug development.

Qualifications

  • PhD, University of Newcastle

Keywords

  • Breast Cancer
  • Cancer
  • Chemotherapy
  • Drug Development
  • Dynamin
  • Glioblastoma
  • PP2A

Fields of Research

Code Description Percentage
111299 Oncology and Carcinogenesis not elsewhere classified 100

Professional Experience

Professional appointment

Dates Title Organisation / Department
1/02/1996 -  Chief Hospital Scientist Calvary Mater Newcastle Hospital
Medical Oncology
Australia

Awards

Research Award

Year Award
2000 Young medical researcher of the year
Unknown
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (51 outputs)

Year Citation Altmetrics Link
2015 Vuong QV, Hirun S, Chuen TLK, Goldsmith CD, Munro B, Bowyer MC, et al., 'Physicochemical, antioxidant and anti-cancer activity of a Eucalyptus robusta (Sm.) leaf aqueous extract', INDUSTRIAL CROPS AND PRODUCTS, 64 167-174 (2015)
DOI 10.1016/j.indcrop.2014.10.061
Co-authors Vanquan Vuong, Anita Chalmers, Michael Bowyer, C Scarlett
2015 Rixson JE, Abraham JR, Egoshi Y, Skelton BW, Young K, Gilbert J, et al., 'The synthesis and biological activity of novel anthracenone-pyranones and anthracenone-furans', Bioorganic and Medicinal Chemistry, (2015)

An efficient and divergent methodology for the synthesis of new anthracenone-pyranones and anthracenone-furans is described. Key reactions discussed in these syntheses include an ... [more]

An efficient and divergent methodology for the synthesis of new anthracenone-pyranones and anthracenone-furans is described. Key reactions discussed in these syntheses include an aldehyde promoted annulation with a ß-keto-sulfoxide, a domino alkyne insertion/carbonylation/Nu-acylation and a DMEDA promoted Castro-Stephens reaction. We also report the in vitro growth inhibition of these compounds in a range of human cancer cells. The natural product BE-26554A displayed good cell growth activity on BE2-C neuroblastoma and SMA glioblastoma cell lines at 0.17 and 0.16µM (GI50), respectively. Of note, were a CF3 functionalised anthracenone 4-pyranone (chromone) derivative 22, and an anthracenone-furan derivative 54 which displayed 0.20µM and 0.38µM growth inhibition, respectively, in the BE2-C neuroblastoma cell line.

DOI 10.1016/j.bmc.2015.04.032
Co-authors Adam Mccluskey
2014 Al Otaibi A, Gordon CP, Gilbert J, Sakoff JA, McCluskey A, 'The influence of ionic liquids on the Knoevenagel condensation of 1H-pyrrole-2-carbaldehyde with phenyl acetonitriles-cytotoxic 3-substituted-(1H-pyrrol-2-yl)acrylonitriles', RSC Advances, 4 19806-19813 (2014) [C1]

The Knoevenagel condensation of a series of substituted phenyl acetonitriles with 1H-pyrrole-2-carbaldehyde was examined in seven 1-butyl-3-methylimidazolium based ionic liquids a... [more]

The Knoevenagel condensation of a series of substituted phenyl acetonitriles with 1H-pyrrole-2-carbaldehyde was examined in seven 1-butyl-3-methylimidazolium based ionic liquids and three protic ionic liquids. Of these [BMIM][Br] and [BMIM][OH], with catalytic piperidine, proved most efficient affording 3-substituted-(1H-pyrrol-2-yl)acrylonitriles 3-17 in good to excellent yields (98%) whilst utilisation of the protic ionic liquid propyl ammonium nitrate resulted in reduced yields (0-66%). Screening of the 3-substituted-(1H-pyrrol-2-yl)acrylonitriles analogues 3-17 against a panel of 11 cancer cell lines and one normal cell line allowed the identification of a series of compounds with broad spectrum cytotoxicity, but more interestingly a significant degree of MCF-7 breast cancer cell line specificity was evident with 6 (7 to >25 fold) and 13 (5.7 to >80 fold). Other analogues show high level of efficacy against specific cell lines with 10 showing excellent activity against MCF-7 (GI50 = 1.7 µM) and A431 (GI50 = 2.8 µM) cell lines. The most promising of the compounds identified herein were the 4-CF3 substituted 10 and the 3,4-dichloro substituted 13 with excellent activities against MCF-7 and A431 cell lines. The 3,4-dichloro-13 was a 0.56 µM potent inhibitor of MCF-7 cell growth. © 2014 the Partner Organisations.

DOI 10.1039/c3ra47418f
Co-authors Adam Mccluskey
2014 Dyson L, Young KA, McCluskey A, Wright AD, Sakoff JA, 'Synthesis and anticancer activity of focused compound libraries from the natural product lead, oroidin', Bioorganic and Medicinal Chemistry, 22 1690-1699 (2014) [C1]

Oroidin (1), (E)-N-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dibromo-1H- pyrrole-2-carboxamide, is a pyrrole alkaloid isolated from the marine sponge Agelas oroides. Routine screeni... [more]

Oroidin (1), (E)-N-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dibromo-1H- pyrrole-2-carboxamide, is a pyrrole alkaloid isolated from the marine sponge Agelas oroides. Routine screening in a panel of twelve cancer cell lines revealed 1 to be poorly cytotoxic with the 50% growth inhibition concentration (GI) of 42 µM in MCF-7 (breast) cells and 24 µM in A2780 (ovarian) cells and >50 µM in all other cell lines tested. The development of eight focused libraries comprising thirty compounds total identified N-(biphenyl-4-ylmethyl)-1H-pyrrole-2-carboxamide (4l), N-benzyl-4,5-dibromo-1H- pyrrole-2-carboxamide (5a) and N-(biphenyl-4-ylmethyl)-4,5-dibromo-1H-pyrrole-2- carboxamide (5l) as potent inhibitors of cell growth in our panel of cell lines. Of these compounds GI values of <5 µM were observed with 4l against HT29 (colon) and SW480 (colon); 5a against HT29; and 5l against HT29, SW480, MCF-7, A431 (skin), Du145 (prostate), BE2-C (neuroblastoma) and MIA (pancreas) cell lines. As a cancer class, colon cancer appears to be more sensitive to the oroidin series of compounds, with analogue 5l being the most active. © 2014 Elsevier Ltd. All rights reserved.

DOI 10.1016/j.bmc.2014.01.021
Citations Scopus - 2Web of Science - 3
Co-authors Adam Mccluskey
2014 Vuong QV, Sadeqzadeh E, Hirun S, Goldsmith CD, Zammitt N, Bowyer MB, et al., 'Phenolic Compounds, Antioxidant and Anti-Cancer Properties of the Australian Maroon Bush Scaevola spinescens (Goodeniaceae)', Journal of Bioanalysis & Biomedicine, S12 (2014) [C1]
DOI 10.4172/1948-593X.S12-002
Co-authors Michael Bowyer, Rick Thorne, C Scarlett, Judith Weidenhofer, Vanquan Vuong
2014 Gordon CP, Hizartzidis L, Tarleton M, Sakoff JA, Gilbert J, Campbell BE, et al., 'Discovery of acrylonitrile-based small molecules active against Haemonchus contortus', MEDCHEMCOMM, 5 159-164 (2014) [C1]
DOI 10.1039/c3md00255a
Citations Scopus - 3Web of Science - 3
Co-authors Adam Mccluskey
2013 Tarleton M, Dyson L, Gilbert J, Sakoff JA, McCluskey A, 'Focused library development of 2-phenylacrylamides as broad spectrum cytotoxic agents', BIOORGANIC & MEDICINAL CHEMISTRY, 21 333-347 (2013) [C1]
DOI 10.1016/j.bmc.2012.10.003
Citations Scopus - 5Web of Science - 4
Co-authors Adam Mccluskey
2013 McCluskey A, Daniel JA, Hadzic G, Ngoc C, Clayton EL, Mariana A, et al., 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', TRAFFIC, 14 1272-1289 (2013)
DOI 10.1111/tra.12119
Citations Web of Science - 21
Co-authors Adam Mccluskey
2013 McCluskey A, Daniel JA, Hadzic G, Chau N, Clayton EL, Mariana A, et al., 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', Traffic, 14 1272-1289 (2013) [C1]
DOI 10.1111/tra.12119
Citations Scopus - 23
Co-authors Adam Mccluskey
2013 Deane FM, O'Sullivan EC, Maguire AR, Gilbert J, Sakoff JA, McCluskey A, McCarthy FO, 'Synthesis and evaluation of novel ellipticines as potential anti-cancer agents', Organic & Biomolecular Chemistry, 11 1334-1344 (2013) [C1]
DOI 10.1039/c2ob27186a
Citations Scopus - 8Web of Science - 9
Co-authors Adam Mccluskey
2013 McGeachie AB, Odell LR, Quan A, Daniel JA, Chau N, Hill TA, et al., 'Pyrimidyn compounds: Dual-action small molecule pyrimidine-based dynamin inhibitors', ACS Chemical Biology, 8 1507-1518 (2013) [C1]
DOI 10.1021/cb400137p
Citations Scopus - 6Web of Science - 6
Co-authors Adam Mccluskey
2012 Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and anticancer activity of a series of norcantharidin analogues', European Journal of Medicinal Chemistry, 54 573-581 (2012) [C1]
Citations Scopus - 8Web of Science - 8
Co-authors Adam Mccluskey
2012 Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Cytotoxic 2-phenyacrylnitriles, the importance of the cyanide moiety and discovery of potent broad spectrum cytotoxic agents', European Journal of Medicinal Chemistry, 57 65-73 (2012) [C1]
DOI 10.1016/j.ejmech.2012.09.019
Citations Scopus - 8Web of Science - 8
Co-authors Adam Mccluskey
2012 Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107 1525-1533 (2012) [C1]
Citations Scopus - 4Web of Science - 6
Co-authors Stephen Ackland, Lisa Lincz
2011 Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879 2201-2205 (2011) [C1]
Citations Scopus - 5Web of Science - 5
Co-authors Stephen Ackland
2011 Tarleton MJ, Gilbert J, Robertson MJ, McCluskey A, Sakoff JA, 'Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound', MedChemComm, 2 31-37 (2011) [C1]
DOI 10.1039/c0md00147c
Citations Scopus - 11Web of Science - 11
Co-authors Adam Mccluskey
2011 Campbell BE, Tarleton MJ, Gordon CP, Sakoff JA, Gilbert J, McCluskey A, Gasser RB, 'Norcantharidin analogues with nematocidal activity in Haemonchus contortus', Bioorganic and Medicinal Chemistry Letters, 21 3277-3281 (2011) [C1]
DOI 10.1016/j.bmcl.2011.04.031
Citations Scopus - 17Web of Science - 19
Co-authors Adam Mccluskey
2011 Robertson MJ, Gordon CP, Gilbert J, McCluskey A, Sakoff JA, 'Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity', Bioorganic & Medicinal Chemistry, 19 5734-5741 (2011) [C1]
DOI 10.1016/j.bmc.2011.01.031
Citations Scopus - 9Web of Science - 10
Co-authors Adam Mccluskey
2010 Joshi S, Perera S, Gilbert J, Smith CM, Mariana A, Gordon CP, et al., 'The Dynamin inhibitors MiTMAB and OcTMAB induce Cytokinesis failure and inhibit cell proliferation in human cancer cells', Molecular Cancer Therapeutics, 9 1995-2006 (2010) [C1]
DOI 10.1158/1535-7163.mct-10-0161
Citations Scopus - 26Web of Science - 29
Co-authors Adam Mccluskey
2010 Thaqi A, Scott JL, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and biological activity of Delta-5,6-norcantharimides: Importance of the 5,6-bridge', European Journal of Medicinal Chemistry, 45 1717-1723 (2010) [C1]
DOI 10.1016/j.ejmech.2010.01.004
Citations Scopus - 20Web of Science - 18
Co-authors Adam Mccluskey
2010 De Bock CE, Garg ML, Scott NM, Sakoff JA, Scorgie FE, Ackland S, Lincz L, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 1-8 (2010) [C1]
DOI 10.1038/tpj.2010.43
Citations Scopus - 7Web of Science - 7
Co-authors Lisa Lincz, Stephen Ackland, Manohar Garg
2009 Sauer B, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis of 4-substituted-3-hydroxy-5-oxo-10-oxa-4-azatricyclo[5.2.1]dec-3-yl Acetic Acid Ethyl Esters as Norcantharidin Analogues', Letters in Drug Design & Discovery, 6 1-7 (2009) [C1]
DOI 10.2174/157018009787158535
Citations Scopus - 7Web of Science - 7
Co-authors Adam Mccluskey
2009 Hill TA, Gordon CP, McGeachie AB, Venn-Brown B, Odell L, Chau N, et al., 'Inhibition of dynamin mediated endocytosis by the dynoles-synthesis and functional activity of a family of indoles', Journal of Medicinal Chemistry, 52 3762-3773 (2009) [C1]
DOI 10.1021/jm900036m
Citations Scopus - 66Web of Science - 62
Co-authors Adam Mccluskey
2009 Holland IP, McCluskey A, Sakoff JA, Gilbert J, Chau N, Robinson PJ, et al., 'Steroids from an Australian Sponge Psammoclema sp', Journal of Natural Products, 72 102-106 (2009) [C1]
DOI 10.1021/np800688f
Citations Scopus - 4Web of Science - 3
Co-authors Adam Mccluskey
2008 Lincz L, Mudge L-M, Scorgie FE, Sakoff JA, Hamilton C, Seldon MR, 'Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the [beta symbol] deletion variant', Neoplasia, 10 1131-1137 (2008) [C1]
DOI 10.1593/neo.08644
Citations Scopus - 21Web of Science - 20
Co-authors Lisa Lincz
2008 Hill TA, Stewart SG, Gordon CP, Ackland SR, Gilbert J, Sauer B, et al., 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem, 3 1878-1892 (2008) [C1]
DOI 10.1002/cmdc.200800192
Citations Scopus - 32Web of Science - 33
Co-authors Stephen Ackland, Adam Mccluskey
2007 Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17 3392-3397 (2007) [C1]
DOI 10.1016/j.bmcl.2007.03.093
Citations Scopus - 49Web of Science - 46
Co-authors Adam Mccluskey, Stephen Ackland
2007 Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15 6126-6134 (2007) [C1]
DOI 10.1016/j.bmc.2007.06.034
Citations Scopus - 51Web of Science - 50
Co-authors Adam Mccluskey, Stephen Ackland
2007 Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry, 15 7301-7310 (2007) [C1]
DOI 10.1016/j.bmc.2007.08.028
Citations Scopus - 33Web of Science - 27
Co-authors Adam Mccluskey, Stephen Ackland
2004 Lincz L, Scorgie F, Sakoff J, Fagan K, Ackland S, Enno A, 'Telomere length predicts neutrophil recovery in absence of G-CSF after autologous peripheral blood stem cell transplantation', Bone Marrow Transplant, 34 439-445 (2004) [C1]
DOI 10.1038/sj.bmt.1704607
Citations Scopus - 3Web of Science - 3
Co-authors Stephen Ackland, Lisa Lincz
2004 Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53 225-232 (2004) [C1]
DOI 10.1007/s00280-003-0730-9
Citations Scopus - 8Web of Science - 7
Co-authors Adam Mccluskey, Stephen Ackland
2004 Hart ME, Chamberlin AR, Walkom CC, Sakoff JA, McCluskey A, 'Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity', Bioorganic & Medicinal Chemistry Letters, 14 1969-1973 (2004) [C1]
DOI 10.1016/j.bmcl.2004.01.093
Citations Scopus - 66Web of Science - 65
Co-authors Adam Mccluskey
2004 Sakoff JA, McCluskey A, 'Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents', Current Pharmaceutical Design, 10 1139-1159 (2004) [C1]
DOI 10.2174/1381612043452686
Citations Scopus - 46Web of Science - 44
Co-authors Adam Mccluskey
2003 Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
DOI 10.1016/S0045-2068(02)00524-2
Citations Scopus - 72Web of Science - 61
Co-authors Michael Bowyer, Adam Mccluskey, Stephen Ackland
2002 McCluskey A, Sim A, Sakoff J, 'Serine-threonine protein phosphatase inhibitors: Development of potential therapeutic strategies', Journal of Medicinal Chemistry, 45 1151-1175 (2002) [C1]
Citations Scopus - 178Web of Science - 176
Co-authors Adam Mccluskey, Alistair Sim
2002 Sakoff J, Ackland S, Baldwin ML, Atherton MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues', Investigational New Drugs, 20 1-11 (2002) [C1]
Citations Scopus - 62Web of Science - 54
Co-authors Mirella Atherton, Stephen Ackland, Adam Mccluskey
2002 McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
Citations Scopus - 27Web of Science - 22
Co-authors Stephen Ackland, Adam Mccluskey
2002 McCluskey A, Atherton MA, Walkom CC, Bowyer M, Sim A, Young D, Sakoff J, 'The first two cantharidin analogues displaying PP1 selectivity', Bioorganic & Medicinal Chemistry Letters, 12 391-393 (2002) [C1]
Citations Scopus - 39Web of Science - 38
Co-authors Adam Mccluskey, Mirella Atherton, Alistair Sim, Michael Bowyer
2002 Garg MB, Sevester JC, Sakoff JA, Ackland SP, 'Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity', JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 774 223-230 (2002)
DOI 10.1016/S1570-0232(02)00239-8
Citations Scopus - 35Web of Science - 30
Co-authors Stephen Ackland
2002 Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, et al., 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10) 2017-2020 (2002) [C1]
Citations Scopus - 22Web of Science - 22
Co-authors Lisa Lincz, Stephen Ackland
2001 McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
Citations Scopus - 55Web of Science - 55
Co-authors Adam Mccluskey, Michael Bowyer, Stephen Ackland
2001 McCluskey A, Sakoff JA, 'Small molecule inhibitors of serine/threonine protein phosphatases.', Mini reviews in medicinal chemistry, 1 43-55 (2001)

Serine/threonine protein phosphatases have long been ignored as potential therapeutic targets for two reasons, one the biochemical significance of these proteins has not been appr... [more]

Serine/threonine protein phosphatases have long been ignored as potential therapeutic targets for two reasons, one the biochemical significance of these proteins has not been appreciated and two, many natural protein phosphatase inhibitors are potent toxins and are considered unsuitable for clinical use. This review outlines the biochemical role of this protein family in cancer, cystic fibrosis, immunosuppression and, cardiac and neurological disorders. Particular emphasis is also given to the synthesis of selective small molecule inhibitors and their clinical exploitation.

Citations Scopus - 56
Co-authors Adam Mccluskey
2000 McCluskey A, Atherton MA, Mudgee L, Sim A, Sakoff JA, Quinn R, 'Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?', European Journal of Medicinal Chemistry, 35 957-964 (2000) [C1]
Citations Scopus - 41Web of Science - 39
Co-authors Alistair Sim, Adam Mccluskey, Mirella Atherton
2000 Sakoff J, Ackland S, 'Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells', Cancer Chemotherapy and Pharmacology, 46 477-487 (2000) [C1]
Citations Scopus - 30Web of Science - 26
Co-authors Stephen Ackland
2000 Bowyer MC, 'Anhydride Modified Cantharidin Analogues: Synthesis, Inhibition of Protein Phosphatases 1 and 2A and Anticancer Activity', Bioorganic & Medicinal Chemistry Letters, 10 1687-1690 (2000) [C1]
Citations Scopus - 69Web of Science - 69
Co-authors Michael Bowyer, Alistair Sim, Adam Mccluskey
2000 Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
Co-authors Stephen Ackland, Adam Mccluskey
1996 Sakoff J, Dunstan RH, Murdoch RN, 'Uterine lipid alterations during early pseudopregnancy and following the artificial induction of decidualization by Concanavalin A in QS mice', Molecular reproductive Development, 44 93-102 (1996) [C1]
Citations Scopus - 1
Co-authors Hugh Dunstan
1996 Sakoff JA, Murdoch RN, 'The role of calcium in the artificially induced decidual cell reaction in pseudopregnant mice', BIOCHEMICAL AND MOLECULAR MEDICINE, 57 81-90 (1996)
DOI 10.1006/bmme.1996.0013
Citations Scopus - 7Web of Science - 8
1996 Sakoff J, Murdoch RN, 'The role of calcium ions in the Concanavalin A induced decidual cell reaction in pseudopregnant mice', Biochemical and Molecular Medicine, 57 81-90 (1996) [C1]
1995 Sakoff J, Murdoch RN, 'Uterine receptivity to the artificial deciduogenic agent, Concanavalin A in pseudopregnant', Reproduction, Fertility and Development, 7 1095-1100 (1995) [C1]
Citations Scopus - 2Web of Science - 2
1994 Sakoff J, Murdoch RN, 'Alterations in uterine calcium ions during the induction of the decidual cell reaction in pseudopregnant mice', journal of reproduction and fertility, 101 97-102 (1994) [C1]
Citations Scopus - 13Web of Science - 14
Show 48 more journal articles

Conference (19 outputs)

Year Citation Altmetrics Link
2014 Sakoff J, Gilbert J, McCluskey A, 'Small molecules selectively targeting breast cancer cells', EUROPEAN JOURNAL OF CANCER, European Org Res & Treatment Canc, Barcelona, SPAIN (2014) [E3]
Co-authors Adam Mccluskey
2014 Garg MB, Sakoff JA, Johnson C, Bonaventura A, Ackland SP, 'CLINICAL STUDY OF MITOTANE PHARMACODYNAMICS IN ADRENOCORTICAL CANCER IN CHILDREN AND ADULTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Stephen Ackland
2014 Gilbert J, Dun MD, De Iuliis GN, McCluskey A, Sakoff JA, 'SELECTIVELY TARGETING BREAST CANCER CELLS VIA CHECKPOINT ACTIVATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Adam Mccluskey, Geoffry DeiuliIs, Matt Dun
2014 Gilbert J, McCluskey A, Sakoff JA, 'ENHANCING RADIATION EFFECTS FOR THE TREATMENT OF BRAIN CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Adam Mccluskey
2014 Prawira A, Garg MB, Sakoff JA, Lincz LF, Adler K, Scorgie FE, Ackland SP, 'FACTORS PREDICTING RESPONSE AND SURVIVAL IN COLORECTAL CANCER PATIENTS RECEIVING ADJUVANT 5-FLUOROURACIL CHEMOTHERAPY: 10-YEAR FOLLOW-UP OF A PROSPECTIVE PATIENT COHORT', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Lisa Lincz, Stephen Ackland
2013 Sakoff JA, Gilbert J, Tarleton M, Robertson M, McCluskey A, 'New small molecules targeting breast cancer', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013) [E3]
Co-authors Adam Mccluskey
2012 Sakoff JA, Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, 'Predicting chemotherapy-induced toxicity in cancer patients from peripheral blood telomere length', European Journal of Cancer, Barcelona, Spain (2012) [E3]
Co-authors Lisa Lincz, Stephen Ackland
2010 Garg M, Sakoff JA, Ackland S, 'A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authors Stephen Ackland
2010 Joshi S, Gaddipatti S, Gilbert J, Smith CM, Gordon CP, Sakoff JA, et al., 'Dynamin inhibition: A new therapeutic approach for the treatment of cancer', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authors Adam Mccluskey
2010 Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Telomere length in peripheral blood mononuclear cells (PBMNC) predicts for leukopenia, neutropenia and mucositis in colorectal cancer patients treated with 5FU', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authors Lisa Lincz, Stephen Ackland
2010 Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Short telomeres in PBMNC predicts for haematological toxicity in colorectal cancer patients treated with 5FU', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authors Lisa Lincz, Stephen Ackland
2010 Chircop M, Perera S, Ma MPC, Lau H, Gilbert J, Jones NC, et al., 'Dynole 34-2 is a potent inhibitor of dynamin that induces cell death following cytokinesis failure and suppresses glioblastoma tumour growth in vivo', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
Co-authors Adam Mccluskey
2002 Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER, FRANKFURT, GERMANY (2002)
Co-authors Stephen Ackland, Adam Mccluskey
1996 Sakoff JA, Murdoch RN, 'Uterine decidualization and calcium ion alterations in pseudopregnant mice' (1996) [E1]
1995 Sakoff JA, Dunstan RH, Murdoch RN, 'The n-3 and n-6 fatty acid profile of uterine tissue following the Concanavalin A induced decidual cell reaction in mice', Unknown, Unknown (1995) [E1]
1995 Sakoff JA, Dunstan RH, Murdoch RN, 'Alterations in uterine saturated fatty acids and cholesterol accompany induction of decidualization in pseudopregnant mice' (1995) [E1]
1994 Sakoff JA, Murdoch RN, 'The period of uterine receptivity in the pseudopregnant Quackenbush Special mouse as defined by the deciduogenic lectin, Concanavalin A' (1994) [E1]
1993 Sakoff JA, Murdoch RN, Dunstan RH, 'Changes in the poly-unsaturated fatty acid composition of the uterus during induction of the decidual cell reaction in pseudopregnant mice', Changes in the poly-unsaturated fatty acid composition of the uterus during induction of the decidual cell reaction in pseudopregnant mice, Unknown (1993) [E1]
1991 Sakoff J, Murdoch RN, 'Uterine decidualization and calcium ion alterations in pseudopregnant mice' (1991) [E1]
Show 16 more conferences
Edit

Grants and Funding

Summary

Number of grants 27
Total funding $2,607,036

Click on a grant title below to expand the full details for that specific grant.


20142 grants / $35,000

Enhancing radiation effects for the treatment of brain cancer $25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301412
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

An Investigation on the Consensus Between Different Genomic and Transcriptomic Results in Breast Cancer$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Ms Heloisa Milioli, Professor Pablo Moscato, Doctor Jennette Sakoff, Associate Professor Regina Berretta
Scheme Jennie Thomas Medical Research Travel Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1401334
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20131 grants / $210,000

The integration of bioinformatics, chemoinformatics, and toxicogenomics methods: a new approach for the identification of combination tailored therapies and novel drug targets in breast cancer$210,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Pablo Moscato, Doctor Jennette Sakoff, Associate Professor Regina Berretta
Scheme NSW Premier's Awards for Outstanding Cancer Research: "Big Data, Big Impact" Grant
Role Investigator
Funding Start 2013
Funding Finish 2014
GNo G1300826
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20127 grants / $755,794

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$245,100

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Ms Megan Chircop, Professor Adam McCluskey, Professor Phillip Robinson, Doctor Jennette Sakoff
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1101106
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200555
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Identification of a novel target for the treatment of hormone positive breast cancer$30,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
Scheme Breast Cancer Project Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200716
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Mitotane pharmacodynamics in Adrenocortical Cancer in children and adults $20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff, Ms MADHU Garg
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200319
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$15,000

Funding body: NSW Trade & Investment

Funding body NSW Trade & Investment
Project Team Professor Adam McCluskey, Doctor Jennette Sakoff
Scheme TechVouchers Program
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200796
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Ultrasonic Homogenizer System and -80 ºC Freezers for chemical and biological sample storage$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Adam McCluskey, Professor Eileen McLaughlin, Professor Peter Lewis, Ms Belinda Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Doctor Ian Grainge
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100986
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20114 grants / $1,054,792

Development of pthaladyn-based dynamin I-selective inhibitors for treatment of epilepsy$544,831

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Adam McCluskey, Professor Phillip Robinson, Professor Terence O'Brien, Ms Megan Chircop, Doctor Jennette Sakoff
Scheme Development Grants
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1000740
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Chemical Biology$444,961

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Doctor Warwick Belcher, Doctor Ian Grainge, Professor Christopher Grof, Professor Peter Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Conjoint Professor Ray Rose, Doctor Jennette Sakoff, Doctor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100052
Type Of Funding Internal
Category INTE
UON Y

Computational prediction and functional clarification of novel drug combination strategies for the treatment of brain tumours$50,000

Funding body: Maitland Cancer Appeal Committee

Funding body Maitland Cancer Appeal Committee
Project Team Professor Pablo Moscato, Mr Dan Johnstone, Associate Professor Regina Berretta, Doctor Luke Mathieson, Professor Manuel Graeber, Doctor Jennette Sakoff
Scheme Research Project
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100275
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Eppendorf mastercycler pro with thermomixer comfort and 5430R centrifuge$15,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Eileen McLaughlin, Professor Peter Lewis, Professor Adam McCluskey, Conjoint Professor Keith Jones, Associate Professor Brett Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Doctor Ian Grainge, Doctor Janet Holt, Doctor Xiao Yang
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100028
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20101 grants / $35,000

New small molecules for the treatment of neuroblastoma$35,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Dr JAYNE Gilbert, Doctor Jennette Sakoff, Ms Megan Chircop
Scheme Paediatric Oncology Project Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G0900192
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20072 grants / $352,000

FACSAria - Fluorescence activated cell sorter$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187666
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188207
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20061 grants / $11,000

Overcoming radiation resistance in malignant melanoma$11,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lisa Lincz, Doctor Jennette Sakoff
Scheme Project Grant
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0186528
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20031 grants / $50,000

High Pressure and Fluorous Approaches to fostriecin libraries: New Therapeutic Opportunities.$50,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Professor Adam McCluskey, Assoc. Prof David Young, Doctor Jennette Sakoff
Scheme Discovery Projects
Role Investigator
Funding Start 2003
Funding Finish 2003
GNo G0182117
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20021 grants / $10,000

New targets for chemotherapy: anti-cancer drugs that target protein phosphatases$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff
Scheme Project Grant
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo G0181459
Type Of Funding Internal
Category INTE
UON Y

20013 grants / $23,450

Synergistic interaction between thymidylate synthase and protein phosphatase inhibition in colon cancer cells$10,450

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Jennette Sakoff
Scheme Early Career Researcher Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0181233
Type Of Funding Internal
Category INTE
UON Y

Predicting bone marrow regeneration in cancer patients through the use of telomere quantitative (Q)-FISH$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lisa Lincz, Doctor Jennette Sakoff
Scheme Lions Club of Stroud
Role Investigator
Funding Start 2001
Funding Finish 2001
GNo G0181502
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Pulse Education Prize for 2001$3,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff
Scheme Research Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0181503
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20003 grants / $45,000

Influence of Haematopoetic stem cell telorase activity on bone marrow recovery following myoablative therapy.$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lisa Lincz, Ms Kerry Fagan, Doctor Jennette Sakoff
Scheme Research Grant
Role Investigator
Funding Start 2000
Funding Finish 2000
GNo G0180171
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

A counter-intuitive anticancer treatment.$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff
Scheme Research Grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo G0180205
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Young Medical Researcher of the Year.$5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff
Scheme Research Grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo G0180182
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

19991 grants / $25,000

Selective Inhibitors of Protein Phosphatases as Anti-cancer agents$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Professor Adam McCluskey, Conjoint Professor Stephen Ackland
Scheme Research Grant
Role Lead
Funding Start 1999
Funding Finish 1999
GNo G0178390
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y
Edit

Research Supervision

Current Supervision

Commenced Research Title / Program / Supervisor Type
2013 Biomarker Discovery in Breast Cancer
Biological Sciences, Faculty of Science and Information Technology
Co-Supervisor
Edit

Dr Jennette Sakoff

Position

Conjoint Lecturer
Experimental Therapeutics Group
School of Environmental and Life Sciences
Faculty of Science and Information Technology

Focus area

Chemistry

Contact Details

Email jennette.sakoff@newcastle.edu.au
Phone (02) 4921 1149
Fax (02) 4968 0384

Office

Building Department of Medical Oncology
Location Calvary Mater Newcastle Hospital

,
Edit